Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Immune Response announces phase IIb trial results for RA

Dec. 23, 1998

New cell adhesion inhibitors in development at Lilly for inflammatory disorders, etc.

Dec. 22, 1998

Another group of MMP inhibitors discovered at Hoechst

Dec. 22, 1998

Compounds for inhibiting matrix metalloproteinases in development at Hoechst Marion Roussel

Dec. 21, 1998

Boehringer Ingelheim submits U.S. NDA for osteoarthritis treatment

Dec. 18, 1998

MMP inhibitors synthesized and evaluated for biological activity at Hoechst Marion Roussel

Dec. 17, 1998

PLA2 inhibitors with broad potential application as antiinflammatory agents

Dec. 16, 1998

Cytogen obtains expanded rights to samarium Sm 153 lexidronam for RA

Dec. 11, 1998

Immune Response receives broader patent protection for RA vaccine technology

Dec. 10, 1998

New approval obtained for Nycomed's Xefo

Dec. 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...